Q4 2024 Earnings Call Transcript March 11, 2025 MaxCyte, Inc. beats earnings expectations. Reported EPS is $-0.1004, ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic ...

Vertex's products are known as cystic fibrosis transmembrane ... The company's blood disorders treatment -- Casgevy -- also is a multibillion-dollar opportunity, according to Vertex.

AWS’s framework will speed up the analysis of ElevateBio’s large protein datasets, hinting at promising drug candidates.

This writer digs into the CRISPR gene-editing space, asking whether one particular penny stock is worth taking a punt on in ...

The Medicines and Healthcare products Regulatory Agency (MHRA) cleared Vertex Pharma and CRISPR Therapeutics' Casgevy (exagamglogene autotemcel or exa-cel) in Great Britain as a one-shot therapy ...

Remarkable technological advancements have shaped the history of medicine for over 150 years. Historical breakthroughs have ...

Transformational drugs rarely emerge from a targeted, application-driven approach. Rather, they arise from deep scientific inquiry over many years, an approach that only robust, early-stage funding ...

Crispr Therapeutics is the only biotech of the three that has a product on the market. Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary ...

On CRSP's fourth-quarter 2024 earnings call, investors' focus will likely be on the sales figure of Casgevy, its first marketed product. We recently compiled a list of the Cathie Wood’s Stock ...

The product has been launched in 35 countries around ... as well as Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia – both autologous cell therapies that seek to address the ...